PSMA as a theranostic target

Prostate cancer is the 3rd lethal type of cancer in the United States. Its diagnostic and stage assessment is done by histological analysis of microbiopsy, imagery, and serum marker evaluation. (1)

Prostate specific membrane antigen (PSMA) a membrane glycoprotein also known as Glutamate carboxypeptidase II (GCPII) is highly associated tumorigenicity of prostate cancer. Its overexpression in neovascularized tumor tissue has also been reported in various types of cancer. (1) Different antibodies and ligands targeting PSMA have been developed during the last 15 years, but their use in diagnostic is more recent. Briefly, gallium 68 labeled ligands are used to label PSMA positive cells in patients and then the detection is done by PET/CT. (2PSMA is an interesting target for a theranostic approaches, a combination of therapy therapy and diagnostic, and some ligands were developed over the years with this idea in mind. Following this concept the PSMA specific ligands discovered could be used for the detection, when radio labeled, and the treatment of the positive patients when coupled with a cytotoxic compound. (3)

MM-0276-P and MM-0277-P have been developed against an epitope located on the extracellular portion of the PSMA. These antibodies have been fully characterized and have shown an excellent specificity to PSMA in a live LNCaP cell line model. (4)

Written by
MédiMabs’ Team